
Aequs Q4 FY26 Results Preview & Earnings Outlook
Updated: 12 Mar 2026 • 5:06 pm
Posted by:

Aequs Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Aequs was listed on the National Stock Exchange (NSE) on 10-Dec-2025. Aequs share has its face value of 10 per share, and its NSE symbol is AEQUS. The company operates in the Industrials sector and primarily belongs to the Precision Engineering industry.
Aequs Q4 Results 2026 Preview
- Aequs Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-15% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 12-17% YoY.
- EBITDA to rise 11-16%.
- Aequs is expected to show Moderate Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Aequs Share Performance
- Over the past six months, Aequs share price has Up by 22% to 119.38.
- Moreover, over the past year, the stock has Up by 38%
- Despite this weak short-term performance, Aequs stock has delivered a financially sound 180% return over the past 5 years.
- As of today, 12-03-2026, the Aequs share price is trading at 119.38 per share.
Key Factors to Watch for Aequs Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Precision Engineering industry within the Industrials sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Aequs
Aequs is a diversified contract manufacturer specializing in precision engineering for aerospace, toys, and consumer durables. It serves global OEMs and multinational brands, offering integrated manufacturing, assembly, and supply chain solutions from its advanced facilities in India.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Aequs is gear up to announce its Q4 FY26 results. Analysts expect 11-15% revenue growth, a 12-17% rise in PAT, and a 11-16% rise in EBITDA. Aequs focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Aequs Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Allied Blenders Q4 FY26 Results: Sales Growth Expectations
Alkem Laboratories Q4 FY26 Results: Earnings Expectations
Akzo Nobel India Q4 FY26 Results: Revenue and Profit Outlook
Aditya Birla Lifestyle Brands Q4 FY26 Results: Revenue Outlook
Aditya Birla Capital Q4 FY26 Results: Revenue and Earnings Outlook
Recent Articles

LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
15 May 2026

Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
15 May 2026

Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
15 May 2026

Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
15 May 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV
Popular this week
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





